Allergan will have the exclusive rights to license certain of Editas' CRISPR genome editing-based treatments for eye diseases.
They successfully edited the gene in mice in vivo and their approach could also work for a range of heterozygous disease-causing SNPs.
Exome sequencing poorly covers some known disease genes, but identifies novel genes that that Harvard team thinks will help improve panel's diagnostic rate.
The partnership will specifically include STP601, Sirnaomics' preclinical treatment for ocular neovascularization diseases, in the Greater China and Southeast Asian markets.
Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.
A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.
An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.
In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.